GaviLyteTM-H and Bisacodyl Delayed-release Tablet was launched by GAVISTM Pharmaceuticals. GaviLyteTM-H with 2-liter volume PEG-3350 and 1 Bisacodyl tablet compares to HalfLytely®.
Methylphenidate Chewable Tablets, 2.5mg, 5 mg & 10 mg, were launched by GAVIS® Pharmaceuticals. Methylphenidate Chewable is AB-rated to Methylin®.
Amlodipine & Valsartan Tablets, 5/160mg, 5/320mg, 10/160mg & 10/320mg, were launched by GAVIS® Pharmaceuticals. Amlodipine & Valsartan is AB rated to Exforge®.
Nystatin Topical Powder USP, 100,000 units per gram (15gm, 30gm & 60gm), were launched by GAVIS® Pharmaceuticals. Nystatin is AT rated to Coastal Pharm’s product and compares to generic Nystop® & NyamycTM.
Levonorgestrel Tablets, 1.5 mg, was launched by GAVIS® Pharmaceuticals. Levonorgestrel, the generic equivalent of the brand product Plan B® and is a women’s healthcare product is intended to prevent pregnancy after known or suspected contraceptive failure or unprotected intercourse. Visit www.mywaypill.com to learn more.
Famotidine for Oral Suspension USP, 40mg/5mL was launched by GAVIS Pharmaceuticals. Famotidine is a gastrointestinal product for long-lasting heartburn relief and is the generic equivalent to the brand Pepcid®.
Misoprostol Tablets, 0.1 mg and 0.2 mg were launched by GAVIS Pharmaceuticals. Misoprostol is the generic equivalent of the brand Cytotec® and is used to help prevent stomach ulcers and stomach irritation in patients taking pain and arthritis drugs, such as aspirin or ibuprofen, for long periods of time.
Tinidazole Tablets, 250 mg and 500 mg were launched by GAVIS Pharmaceuticals. Tinidazole treats infections caused by protozoa (tiny, one-celled animals) and also treats vaginal infections caused by bacteria. This medicine belongs to a class of drugs called antibiotics and is the generic equivalent to the brand Tindamax®. GAVIS Pharmaceuticals received Paragraph IV Certifications for approval of Tindamax®.
Polyethylene Glycol 3350 (Sodium Sulfate, Sodium Chloride, Potassium Chloride,
Sodium Ascorbate, and Ascorbic Acid for Oral Solution) or PEG-3350 is a powder for solution, bottles & unit dose pouch and is the generic equivalent of the brand name MiraLAX®, an over the counter medicine for constipation. GAVIS Pharmaceuticals received Paragraph IV Certifications for approval of PEG-3350.
Trimethoprim tablets, 100mg, were launched by GAVIS® Pharmaceuticals. Trimethoprim treats urinary tract infections and treats ear infections in children and is the generic equivalent to the brands Proloprim® and Trimpex®
Methylergonovine Maleate 0.2mg tablets were launched by GAVIS Pharmaceuticals. Methylergonovine brand prevents bleeding from the uterus that can happen after childbirth. This medicine is an ergot alkaloid and is the generic equivalent to the brand Methergine®.
Quinapril & HCTZ Tablets 10/12.5mg, 20/12.5mg & 20/25mg were launched by GAVIS. Quinapril lowers blood pressure and also relieves symptoms of fluid retention and is the generic equivalent to the brand Accuretic®.
Trimethoprim tablets USP, 100 mg, were launched by GAVIS Pharmaceuticals. Trimethoprim treats urinary tract infections and also treats ear infections in children. It belongs to a group of drugs called antibacterials and is the generic equivalent to the brand Proloprim®/Trimpex®.
GAVIS launched three new products: Hydrocodone 5mg & Homatropine 1.5 mg, Pentazocine 50 mg & Naloxone 0.5 mg and Pentazocine 25 mg & APAP 650 mg. Hydrocodone is the generic equivalent of the brand Tussigon®. Pentazocine/APAP is the generic equivalent to the brand Talacen®. Pentazocine/Naloxone is the generic equivalent of the brand TalwinNx®.
Phenelzine Sulfate 15mg Tablets was launched by GAVIS Pharmaceuticals. Phenelzine is the therapeutic equivalent to Nardil®. It is used to treat depression refractory to other forms of treatment.
GAVIS acquired 5 Abbreviated New Drug Applications. These products planned to launch in early 2011.
Mesalamine Rectal Suspension Enema was launched by GAVIS Pharmaceuticals. Mesalamine is the therapeutic equivalent to Rowasa®. It is used to treat ulcerative colitis. GAVIS Pharmaceuticals also planned to launch 8 to 10 additional products throughout 2010.
Orphenadrine Citrate 100mg ER Tablets was launched by GAVIS Pharmaceuticals. Orphenadrine is the therapeutic equivalent to Norflex®. It is used for pain relief. GAVIS also announced the introduction of Mesalamine Rectal Suspension Enema, the authorized generic version of Rowasa®.
GAVIS completed the acquisition of Orphenadrine Citrate 100mg ER Tablets ANDA from Actavis Totowa.
GAVIS launched its first over-the-counter product, a therapeutic equivalent to MiraLAX® OTC called GaviLAX. This product became available the day after the expiration of the exclusivity period for MiraLAX® and is being sold under various private labels through GAVIS’s marketing partner, Inverness Medical Nutritionals Group. GAVIS also launched Temazepam 15mg and 30mg Capsules, CIV, through marketing partner Ascend Laboratories. Temazepam is used for the treatment of insomnia. Its therapeutic equivalent is Restoril®.
Nifedipine Soft Gelatin Capsules was launched by GAVIS Pharmaceuticals , therapeutic equivalent to Procardia®. Nifedipine is used to treat angina and high blood pressure.
GaviLyte-G and GaviLyte-C was launched by GAVIS Pharmaceuticals; their therapeutic equivalents are GoLYTELY® and Colyte® respectively. Both are used for bowel preparation for gastrointestinal procedures.
May 29, 2009
GAVIS Pharmaceuticals shipped its first product, GaviLyte-N, which is the therapeutic equivalent to NuLytely®. GaviLyte-N is used for bowel preparation for gastrointestinal procedures.
GAVIS completed construction and opened the doors to its 40,000 square foot packaging, warehousing and distribution facility.
GAVIS took up a new warehousing facility on same campus.
GAVIS Pharmaceuticals opened its doors as a new pharmaceutical sales and marketing company with industry veterans in the lead.